Chinese Peptide Company (Medtide)

Peptide CRDMO based in Hangzhou and wholly owned subsidiary of Medtide Inc. (HKEX:03880). Passed FDA on-site inspection in 2024; Tirzepatide API DMF 043979 filed May 2026. Metric-ton-scale cGMP manufacturing serving 1,000+ customers across 50+ countries, covering discovery synthesis through commercial supply.

Directory assessment: Chinese Peptide Company (Medtide) is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Hangzhou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.